-
1.发明公开
-
公开(公告)号：EP3386522A1
公开(公告)日：2018-10-17
申请号：EP16874010.8
申请日：2016-12-09
IPC分类号： A61K35/17 , A61K39/395 , A61K39/00 , A61K31/337
CPC分类号： A61K35/17 , A61K31/337 , A61K39/001106 , A61K39/3955 , A61K45/06 , A61K2039/5156 , A61P35/00 , C07K16/32 , C07K2317/24 , C07K2317/76 , A61K2300/00
摘要： Contemplated immunotherapies include co-administration of an activated NK cell that is further genetically modified and a cancer therapeutic agent. In preferred embodiments, activated NK cells are further modified to taNK cells, which include a chimeric antigen receptor (CAR) with affinity for a cancer specific antigen, a cancer associated antigen, or a tumor specific antigen. Activated NK cells can also be further genetically modified to include high affinity Fc receptor CD16a (V158). Appropriate cancer therapeutic agents include chemotherapeutic drugs (e.g., nant-paclitaxel) or cancer targeted antibodies (e.g., trastuzumab).
-
公开(公告)号：EP4216996A1
公开(公告)日：2023-08-02
申请号：EP21873652.8
申请日：2021-10-22
IPC分类号： A61K39/215 , A61K39/145 , A61K9/48 , A61P31/14 , C07K14/005 , C12N15/86 , C12N9/48
-
-
公开(公告)号：EP3688022A2
公开(公告)日：2020-08-05
申请号：EP18861955.5
申请日：2018-09-28
申请人： NantCell, Inc.
IPC分类号： C07K14/495 , C07K14/54 , C07K14/705 , C12N5/0783 , A61K38/17 , A61K38/18 , A61K38/20
-
公开(公告)号：EP3601538A1
公开(公告)日：2020-02-05
申请号：EP18776060.8
申请日：2018-03-26
申请人： Nantcell, Inc.
IPC分类号： C12N5/0783 , C12N15/86 , C07K14/54 , A61K35/17 , A61P35/00
-
公开(公告)号：EP3411474A1
公开(公告)日：2018-12-12
申请号：EP17748289.0
申请日：2017-02-03
IPC分类号： C12N5/0783 , C12N7/00 , C07K14/705 , C07K14/725 , A61K35/17
CPC分类号： C12N5/0646 , A61K35/17 , C07K14/70503 , C12N5/0635 , C12N5/0636 , C12N5/0639 , C12N2510/00 , C12N2710/10343
摘要： Recombinant expression of CXADR in a cell, and especially an immune competent cell is employed to enable or improve gene delivery to the cell by an adenovirus. In particularly preferred aspects, the immune competent cell is a an NK cell, a T-cell, a B-cell, a macrophage, or a dendritic cell, and the gene delivery comprises a recombinant nucleic acid encoding a disease-specific antigen, such as a patient specific neoepitope or a tumor associated antigen.
-
公开(公告)号：EP4118109A1
公开(公告)日：2023-01-18
申请号：EP21716884.8
申请日：2021-03-11
申请人： NantCell, Inc.
发明人： NELSON, Jay Gardner , BUZKO, Oleksandr , HIGASHIDE, Wendy M. , NIAZI, Kayvan , OLSON, Clifford Anders , SOON-SHIONG, Patrick , TANAKA, Shiho
IPC分类号： C07K16/10 , C12N9/48 , A61K39/00 , A61K39/215
-
公开(公告)号：EP3938495A1
公开(公告)日：2022-01-19
申请号：EP20784677.5
申请日：2020-02-27
申请人： Nantcell, Inc. , NantBio, Inc. , Nantkwest, Inc.
IPC分类号： C12N5/0783 , C07K14/54 , C07K14/735 , C07K14/705 , A61K35/17 , A61P35/00
-
公开(公告)号：EP3735984A1
公开(公告)日：2020-11-11
申请号：EP20179172.0
申请日：2017-05-26
IPC分类号： A61K39/00 , C12N15/86 , C07K14/705 , C07K14/54 , C07K14/715
摘要： In certain embodiments, methods and compositions are provided for generating immune responses against tumor neo-antigens or neo-epitopes. In particular embodiments there may be provided methods for constructing and producing recombinant adenovirus-based vector vaccines containing nucleic acid sequences encoding tumor neo-antigens and neo-epitopes that allow for vaccinations in individuals with preexisting immunity to adenovirus. In additional embodiments, methods and compositions are provided for the treatment of cancer using immunotherapy based on recombinant adenovirus-based vectors combined with engineered natural killer cells. In some embodiments, the methods and compositions further comprises a nucleic acid encoding for an immunological fusion partner.
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.018 秒)
